The early bactericidal activity of antituberculosis drugs (Q38176039)

30 August 2017

The early bactericidal activity of antituberculosis drugs (English)

1 reference

30 August 2017

Andreas H Diacon

1

1 reference

PubMed ID

24392698

30 August 2017

Peter R Donald

series ordinal

2

1 reference

30 August 2017

6 January 2014

1 reference

Expert Review of Anti-infective Therapy

30 August 2017

1 reference

30 August 2017

12

1 reference

30 August 2017

2

1 reference

30 August 2017

223-237

1 reference

Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid.

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Effect of streptomycin on experimental tuberculosis in guinea-pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Activity of amoxicillin/clavulanate in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Diarylquinolines target subunit c of mycobacterial ATP synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Phase II dose-ranging trial of the early bactericidal activity of PA-824

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

The early bactericidal activity of anti-tuberculosis drugs: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of antituberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870884

10.1586/14787210.2014.870884

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24392698